Loading...
Loading...
Jazz Pharmaceuticals plc
fell in the extended session Tuesday after the drug maker posted an outlook below expectations.
The Ireland-based company also said it voluntarily suspended patient enrollment in a Phase 2 trial of its leukemia drug, JZP-416, based on negative reactions in some patients.
The company is evaluating whether to resume the study, which began in the fourth quarter.
Shares of the Dublin, Ireland-based company changed hands recently at $171.51, down more than 2 percent.
The company forecast 2015 adjusted earnings of between $9.45 and $9.75 a share, on revenue of $1.31 billion to $1.37 billion.
Analysts expect 2015 adjusted earnings of $10.11 a share, on revenue of $1.4 billion.
For the recent fourth quarter, net income grew to $81.6 million, or $1.30 a share, from $55.3 million, or $0.90 cents a share a year earlier.
Adjusted profit for the recent period equaled $2.44 a share, while revenue increased 39 percent to $328.1 million, from $235.8 million last year.
Wall Street expected fourth-quarter earnings of $2.30 a share, on revenue of $319.1 million.
The company said it voluntarily suspended patient enrollment in the pivotal Phase 2 clinical trial of one of its leukimia drug, JZP-416, based on occurrence of hypersensitivity-like reactions in some patients.
The company is evaluting data to decide whether to resume the study.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in